Table 1.
Baseline characteristics of the patients.
| Characteristics | No. of patients (%) | ||
|---|---|---|---|
| PD-1 blockade alone | PD-1 blockade-based combination | P value | |
| Gender | 0.764 | ||
| Male | 17 (33.3%) | 7 (13.7%) | |
| Female | 21 (41.2%) | 6 (11.8%) | |
| Age, mean (range) | 56 (28–81) | 51 (28–69) | 0.212 |
| ECOG status | 0.176 | ||
| 0–1 | 26 (50.9%) | 6 (11.8%) | |
| ≥2 | 12 (23.5%) | 7 (13.7%) | |
| Primary sites | 0.979 | ||
| Acral | 12 (23.5%) | 4 (7.8%) | |
| Mucosal | 13 (25.5%) | 4 (7.8%) | |
| CSD/non-CSD | 13 (25.5%) | 5 (9.8%) | |
| Metastatic sites | |||
| Liver | 9 (17.6%) | 6 (11.8%) | 0.176 |
| Lung | 16 (31.4%) | 6 (11.8%) | 0.611 |
| Bone | 9 (17.6%) | 3 (5.9%) | 0.864 |
| Brain | 5 (9.8%) | 0 (0%) | 0.153 |
| Lymph nodes | 25 (49.0%) | 11 (21.6%) | 0.16 |
| LDH level | 0.014 | ||
| ≤UNL | 30 (58.8%) | 5 (9.8%) | |
| >UNL | 8 (15.7%) | 8 (15.7%) | |
| CRP level | 0.140 | ||
| ≤UNL | 28 (54.9%) | 6 (11.8%) | |
| >UNL | 10 (19.6%) | 7 (13.7%) | |
| ALB level | 0.561 | ||
| ≥NLL | 34 (66.7%) | 12 (23.5%) | |
| <NLL | 4 (7.8%) | 1 (2.0%) | |
| NLR | 0.574 | ||
| ≥2.3 | 16 (31.4%) | 6 (11.8%) | |
| <2.3 | 22 (43.1%) | 7 (13.7%) | |
| PLR | 0.406 | ||
| ≥162.5 | 15 (29.4%) | 7 (13.7%) | |
| <162.5 | 23 (45.1%) | 6 (11.8%) | |
| BRAF V600E status | 0.761 | ||
| Mutation | 9 (17.6%) | 2 (3.9%) | |
| Wild-type | 14 (27.5%) | 6 (11.8%) | |
| Unknown | 15 (29.4%) | 5 (9.8%) | |
| PD-1 blockade agents | 0.189 | ||
| Nivolumab | 24 (47.1%) | 6 (11.8%) | |
| Pembrolizumab | 14 (27.5%) | 7 (13.7%) | |
| Treatment-naïve | 0.961 | ||
| Yes | 22 (43.1%) | 8 (15.7%) | |
| No | 16 (31.4%) | 5 (9.8%) | |
ECOG: Eastern Cooperative Oncology Group; CSD: chronic sun-damaged; LDH: lactate dehydrogenase; CRP: C-reactive protein; UNL: upper normal limit; LNL: lower normal limit; ALB: albumin. All P values were two-tailed.